These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 27023842)

  • 1. [Actual medical care situation and therapeutic needs in multiple sclerosis: Impact of the Pharmaceutical Market Restructuring Act (AMNOG)].
    Bittner S; Meuth SG
    Nervenarzt; 2016 Apr; 87(4):394-401. PubMed ID: 27023842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of the German Act on the reform of the market for medicinal products (AMNOG) on the quality of neurological and psychiatric treatment].
    Hamer H; Meyer-Lindenberg A
    Nervenarzt; 2016 Apr; 87(4):351-2. PubMed ID: 27025218
    [No Abstract]   [Full Text] [Related]  

  • 3. [Requirements for drug approval and additional benefits assessment: Regulatory aspects and experiences].
    Broich K; Löbker W; Schulte A; Beinlich P; Müller T
    Nervenarzt; 2016 Apr; 87(4):376-85. PubMed ID: 27003322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The new German drug market law AMNOG from a child and adolescent psychiatry perspective].
    Dittmann RW
    Nervenarzt; 2016 Apr; 87(4):367-75. PubMed ID: 26992908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Impact of early benefit assessment on patients with epilepsy in Germany: Current healthcare provision and therapeutic needs].
    Strzelczyk A; Hamer HM
    Nervenarzt; 2016 Apr; 87(4):386-93. PubMed ID: 26927680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Significance of the German Act on the Reform of the Market for Medicinal Products for psychopharmacotherapy].
    Gründer G
    Nervenarzt; 2016 Apr; 87(4):356-66. PubMed ID: 26983820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Earlier value assessment of pharmaceutical products and medical science].
    Selbmann HK
    Nervenarzt; 2016 Apr; 87(4):353-5. PubMed ID: 27000270
    [No Abstract]   [Full Text] [Related]  

  • 8. Early benefit assessment of pharmaceuticals in Germany: manufacturers' expectations versus the Federal Joint Committee's decisions.
    Fischer KE; Stargardt T
    Med Decis Making; 2014 Nov; 34(8):1030-47. PubMed ID: 25149822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?
    Büssgen M; Stargardt T
    Appl Health Econ Health Policy; 2023 Sep; 21(5):751-759. PubMed ID: 37249741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of a possible predictor for Federal Joint Committee decisions on early benefit assessments according to the German act on the reform of the market for medicinal products.
    Schwander B; Banz K; Kaier K; Walzer S
    Health Policy; 2014 Sep; 117(3):334-44. PubMed ID: 25059744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early benefit assessment of new drugs in Germany - results from 2011 to 2012.
    Hörn H; Nink K; McGauran N; Wieseler B
    Health Policy; 2014 Jun; 116(2-3):147-53. PubMed ID: 24472328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Varying results of early benefit assessment of newly approved pharmaceutical drugs in Germany from 2011 to 2017: A study based on federal joint committee data.
    Peinemann F; Labeit A
    J Evid Based Med; 2019 Feb; 12(1):9-15. PubMed ID: 30701688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The AMNOG and its consequences].
    Dingermann T
    Internist (Berl); 2013 Jun; 54(6):769-74. PubMed ID: 23475259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Information on new drugs at market entry: retrospective analysis of health technology assessment reports versus regulatory reports, journal publications, and registry reports.
    Köhler M; Haag S; Biester K; Brockhaus AC; McGauran N; Grouven U; Kölsch H; Seay U; Hörn H; Moritz G; Staeck K; Wieseler B
    BMJ; 2015 Feb; 350():h796. PubMed ID: 25722024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Drug assessment: IQWiG, G-BA, and an international comparison].
    Glaeske G
    Internist (Berl); 2016 Jan; 57(1):94-101. PubMed ID: 26502888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Four years of early benefit assessment of new drugs in Germany: a qualitative study on methodological requirements for quality of life data.
    Blome C; Augustin M; Metin H; Lohrberg D
    Eur J Health Econ; 2017 Mar; 18(2):181-193. PubMed ID: 26837412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislation.
    Ruof J; Schwartz FW; Schulenburg JM; Dintsios CM
    Eur J Health Econ; 2014 Jul; 15(6):577-89. PubMed ID: 23771769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Patient-relevant outcomes and surrogates in the early benefit assessment of drugs: first experiences].
    Kvitkina T; ten Haaf A; Reken S; McGauran N; Wieseler B
    Z Evid Fortbild Qual Gesundhwes; 2014; 108(8-9):528-38. PubMed ID: 25523852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.